Trial reportEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2022
Tranexamic acid safely reduces hidden blood loss in patients undergoing intertrochanteric fracture surgery: a randomized controlled trial.
Trial report in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Efficacy and safety of Tranexamic acid use on postoperative blood transfusion in hip fracture patients- a systematic review and meta-analysis.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2025Pooled it
- Impact of tranexamic acid on hidden blood loss in intertrochanteric fractures: a meta-analysis of randomized controlled trials.Frontiers in surgery · 2025Pooled it
- Intravenous application of tranexamic acid in intramedullary nailing for the treatment of geriatric intertrochanteric fractures: a systematic review and meta-analysis.BMC musculoskeletal disorders · 2023Pooled it
- Pharmacological interventions for the prevention of bleeding in people undergoing definitive fixation or joint replacement for hip, pelvic and long bone fractures.The Cochrane database of systematic reviews · 2023Pooled it
- Efficacy and safety of tranexamic acid for patients with intertrochanteric fractures treated with intramedullary fixation: A systematic review and meta-analysis of current evidence in randomized controlled trials.Frontiers in pharmacology · 2022Pooled it
- Perioperative Administration of Tranexamic Acid and Low Molecular Weight Heparin for Enhanced Blood Management in Intertrochanteric Fractures: A Randomized Controlled Study.Medical science monitor : international medical journal of experimental and clinical research · 2024Trial
- Tranexamic Acid for Reduction of Blood Loss in Patients with Extracapsular Proximal Femur Fractures: Systematic Review and Meta-Analysis of Randomized Clinical Trials.Pharmaceutics · 2026Article
- Fracture stability modifies the risk profile and outcomes of proximal femoral nailing versus hemiarthroplasty for elderly intertrochanteric fractures.BMC musculoskeletal disorders · 2026Article
- Comparative efficacy of intravenous, topical, and combined tranexamic acid in elderly patients with intertrochanteric fractures undergoing intramedullary nail fixation: a multicenter cohort study.Frontiers in pharmacology · 2026Article
- Safety and efficacy of tranexamic acid in hip hemiarthroplasty: A retrospective review of perioperative outcome.Medicine · 2025Observational
- Predictive value of stress hyperglycemia ratio for perioperative hidden blood loss in patients with hip fractures: a retrospective cohort study.Frontiers in medicine · 2025Article
- A Comparative Study of the Early Postoperative Outcome of Three Intramedullary Fixation Modalities in the Treatment of Intertrochanteric Fractures of the Femur in the Elderly.Journal of musculoskeletal & neuronal interactions · 2024Article
- The emerging role of tranexamic acid and its principal target, plasminogen, in skeletal health.Acta pharmaceutica Sinica. B · 2024Review
- Risk Factors of Hidden Blood Loss in Unilateral Biportal Endoscopic Surgery for Patients with Lumbar Spinal Stenosis.Orthopaedic surgery · 2024Article
- Interventions for reducing red blood cell transfusion in adults undergoing hip fracture surgery: an overview of systematic reviews.The Cochrane database of systematic reviews · 2023Review
- Focus on geriatric proximal femur fractures: factors that influence the outcome.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2022Article
- Comment on article by Shodipo et al.: comparison of single versus double tranexamic acid dose regimens in reducing post-operative blood loss following intramedullary nailing of femoral fracture nonunions.International orthopaedics · 2022Article
- Effectiveness and Safety of Tranexamic Acid Use in Acute Traumatic Injury in the Prehospital and In-hospital Settings: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.Annals of surgery open : perspectives of surgical history, education, and clinical approaches · 2021Article
- Optimal surgical methods to treat intertrochanteric fracture: a Bayesian network meta-analysis based on 36 randomized controlled trials.Journal of orthopaedic surgery and research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo investigate the efficacy and safety of intravenous tranexamic acid (IV-TXA) in patients undergoing intertrochanteric fracture surgery.
methodsA total of 122 patients were included in this double-blinded trial and equally randomized to receive 1 g of IV-TXA or normal saline 10 min before incision and 3 h later. The primary efficacy outcome was calculated hidden blood loss (HBL). The secondary efficacy outcome was allogeneic erythrocyte transfusion rate during hospitalization. Safety outcome was a composite of thromboembolic events including deep venous thrombosis (DVT) up to 90 days. A meta-analysis combining this study with previous randomized controlled trials in hip fracture surgery (total sample size: 1112 patients) was also conducted.
resultsThe mean HBL in TXA group (640.96 ± 421.63 ml) was significantly lower than that in placebo group (1010.11 ± 398.96 ml, P < 0.001). The rate of erythrocyte transfusions was 29.5% in TXA group and 60.7% in placebo group (P = 0.001). The incidence of thromboembolic events at 90 days was 4.9% in TXA group and 1.6% in placebo group (P = 0.619). The updated meta-analysis showed that IV-TXA significantly reduced erythrocyte transfusion in hip fracture surgery (risk ratio 0.60, 95% confidence intervals 0.53-0.68), and IV-TXA caused no increased risk of thromboembolic events (risk difference 0.01, 95% confidence intervals - 0.02-0.04).
conclusionIV-TXA could effectively reduce the HBL and allogeneic erythrocyte transfusion requirements in patients undergoing intertrochanteric fracture surgery without an increase of thromboembolic events including DVT.
trial registrationClinical trials: safety and efficiency of tranexamic acid in hip fracture patients. Date of registration: August 31, 2018. TRIAL REGISTRATION NUMBER: ChiCTR1800018110.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.